icosapent ethyl / Generic mfg. - LARVOL DELTA

Oxidative lipoprotein remodelling in atherogenesis: Mechanistic insights and therapeutic potential. (PubMed, Biochim Biophys Acta Mol Basis Dis) - "Emerging therapeutic approaches, including proprotein convertase subtilisin kexin9 (PCSK9) inhibition, icosapent ethyl, omega-3 fatty acids, nutraceutical antioxidants, and RNA-based strategies, show potential in targeting oxidative lipoprotein pathways, although their efficacy varies across biological and clinical contexts. Collectively, these findings position oxidative lipoprotein modification as a biologically relevant and potentially modifiable dimension of atherogenic risk, supporting its integration into future cardiovascular risk assessment and intervention strategies."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • Metabolic Disorders

The Ischemia-Plaque Paradox: A Mechanistic Framework for Chronic Coronary Syndromes. (PubMed, Cardiol Rev) - "Modern medical therapy with high-intensity lipid lowering, icosapent ethyl in selected patients, anti-inflammatory approaches, and therapies for diabetes and chronic kidney disease has lowered overall event rates...Plaque instability causes infarction and is modified by systemic therapy. Bypass surgery in selected patients with complex coronary anatomy addresses both mechanisms by relieving flow limitation and protecting myocardium against future plaque events."

Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Myocardial Infarction • Nephrology

Expert consensus on initial combination lipid-lowering therapy in patients with type 2 diabetes mellitus and hypertension (2026) (PubMed, Zhonghua Nei Ke Za Zhi) - "The consensus emphasizes that, on the basis of lifestyle interventions, active initiation of combination therapy with statins and cholesterol absorption inhibitors, supplemented with proprotein convertase subtilisin/kexin type 9 inhibitors when necessary, should be implemented to reduce LDL-C to target levels as early as possible. For patients with hypertriglyceridemia, the addition of icosapent ethyl or fibrates is recommended to further reduce residual cardiovascular risk or the risk of pancreatitis."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Hypertension • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Type 2 Diabetes Mellitus

Secondary prevention lipid management after ACS at a DGH: a quality improvement project. (PubMed, Br J Cardiol) - "Many patients fail to achieve therapeutic lipid lowering. Strategies to address this are urgently required."

Journal • Acute Coronary Syndrome • Cardiovascular

Real-world use of Omega-3 fatty acids: a population-based study in an Italian local health unit from Northern Italy. (PubMed, Nutr Metab Cardiovasc Dis) - "EPA/DHA were frequently prescribed outside current guideline recommendations, particularly as monotherapy in high-risk secondary CV prevention patients. These findings highlight a gap between evidence-based guidance and clinical practice and emphasize the need to improve prescribing appropriateness."

Journal • Real-world evidence • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis

Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT. (PubMed, J Clin Lipidol) - "Among individuals at high cardiovascular risk with hypertriglyceridemia and controlled LDL-C on statin therapy, considerable variability was observed over 24 months. These findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics."

Journal • Cardiovascular • Dyslipidemia • Hypertriglyceridemia

Eicosapentaenoic acid (EPA) limits rapid oxidation of lipoprotein(a) [Lp(a)] yielding favorable changes in endothelial cell protein expression that may contribute to clinical benefits (ESC 2026) - "Background: In REDUCE-IT, the omega-3 fatty acid EPA (20:5, n-3) delivered as icosapent ethyl reduced CV events in high-risk patients, including those with elevated Lp(a)... Lp(a) underwent rapid oxidation compared with LDL - possibly due to higher oxidized lipid content - that was inhibited by EPA but not by ALA or probucol. Lp(a), but not LDL, significantly modulated certain stress response proteins under oxidized conditions in ECs that were reversed by EPA. The beneficial effects of EPA on Lp(a)/LDL oxidation and subsequent protein expression may contribute to mechanisms of CV event reduction, including in patients with elevated Lp(a) and/or LDL (REDUCE-IT)."

Clinical • IO biomarker • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • APOB • BAG1 • BCL2 • HSPH1

Effects of icosapent ethyl on coagulation biomarkers and their association with event‑free survival in high‑risk cardiovascular patients: a post hoc analysis of the REDUCE-IT (ESC 2026) - "IPE reduces circulating TF levels in a subset of high‑risk CV patients of the REDUCE-IT; similarly, it reduces TF in HAECs exposed to TNF-α. Patients with higher baseline TF demonstrated more favorable event‑free survival under IPE treatment, whereas the placebo‑high baseline TF subgroup exhibites the greatest incidence of events. The findings herein offer an additional mechanistic explanation for the MACE reduction reported in REDUCE-IT and support an antithrombotic effect of IPE, especially among patients with high baseline TF."

Biomarker • Clinical • Retrospective data • Cardiovascular • Dyslipidemia • Myocardial Infarction • TNFA

Serious adverse events, hospitalization, and mortality associated with icosapent ethyl: a pharmacovigilance analysis using the FDA adverse event reporting system (ESC 2026) - "IPE demonstrated serious adverse event reporting patterns similar to other omega-3 fatty acids and PCSK9 inhibitors, and markedly lower than statins and fibrates. For mortality, IPE occupied an intermediate position among lipid-lowering therapies. Post-REDUCE-IT attenuation of the mortality signal likely reflects indication expansion to higher-risk populations and increased prescribing volume rather than a true safety change, underscoring the need for controlled epidemiological studies with appropriate denominators."

Adverse events • Clinical • Serious adverse event • Atrial Fibrillation • Cardiovascular • Dyslipidemia • ROR1

Effects of residual risk–targeted therapies on coronary plaque regression: a network meta-analysis of 40 studies (ESC 2026) - "A total of 30 RCTs and 10 observational studies testing 7 treatment strategies (i.e., ezetimibe, eicosapentaenoic acid [EPA], glucagon-like peptide-1 receptor agonists [GLP-1 RAs], icosapent ethyl [IPE], proprotein convertase subtilisin/kexin type 9 inhibitors [PCSK9i], polyunsaturated fatty acids [PUFA], colchicine and sodium–glucose cotransporter 2 inhibitors [SGLT2i]) were included in the network (Figure 1). Conclusion. Among patients with coronary artery disease receiving residual risk–targeted therapies on top of statin treatment, PCSK9i, IPE, and SGLT2i, were associated with the greatest degrees of plaque regression."

Retrospective data • Cardiovascular • Coronary Artery Disease

Sex differences in early study discontinuation and study drug withdrawal: insights from REDUCE-IT (ESC 2026) - "Whether this represents a broader phenomenon and the factors underlying these differences remain uncertain.PurposeTo assess whether sex differences in retention observed in coronary artery disease trials apply to the REDUCE-IT trial, which includes patients with both established and high-risk CVD.MethodsPost hoc analysis of the randomised, double-blind, placebo-controlled REDUCE-IT trial of statin-treated patients with established CVD or diabetes plus additional risk factors, controlled LDL cholesterol, and moderately elevated triglycerides, randomised to icosapent ethyl 4 g daily or placebo...The multivariable model adjusted for covariates identified as significant in univariable analyses (including treatment allocation, eGFR, and smoking status) and was stratified by geographic region, cardiovascular risk, and ezetimibe use.ResultsAmong 8,179 participants, 28.8% were women...This reduced their representation and exposure over time, potentially affecting..."

Cardiovascular • Coronary Artery Disease

Lipid assessment and target attainment in acute coronary syndrome: a 10-year comparative review in a UK tertiary centre. (ESC 2026) - "In 2025/26, guidelines were updated to incorporate newer agents (bempedoic acid and icosapent ethyl), pathology request forms were posted directly to patients to facilitate follow-up testing, and an Inclisiran service was established.We evaluated rates of inpatient lipid profiling, repeat lipid measurement at three months, and attainment of guideline-recommended LDL-C targets before and after intervention.ResultsThe mean age for the 2015/16 cohort was 62.2 ± 12.3 years, compared to 67.1 ± 12.4 years in the 2025/26 cohort. While incorporation of newer therapies has modestly increased attainment of contemporary LDL-C targets, a substantial gap persists. Continued systematic, protocol-driven approaches are required to align clinical practice with evolving guideline standards."

Review • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia

Adherence and legacy effects of high dose eicosapentaenoic acid in hypertriglyceridemia and high CV risk – REDUCE-IT Legacy (ESC 2026) - "Analysis of initially adherent subjects who stop study drug can reveal possible persisting benefits of treatment.Purpose: This analysis of REDUCE-IT evaluated the effect of icosapent ethyl (IPE) in subjects with good adherence... Good adherers who took IPE for ≥1.5 years achieved about a 30% risk reduction. Secondary prevention participants who stopped IPE prematurely after a mean of 2.3 years on treatment exhibited a ‘legacy’ effect with no apparent diminution in the HR difference over the next 1 to 4 years. This therapeutic response (analogous to statins) suggests that IPE altered the trajectory of disease."

Adherence • Cardiovascular • Dyslipidemia

Pancreatitis and Mortality Outcomes With Icosapent Ethyl Compared With Fibrates in Severe Hypertriglyceridemia: A Real-World Propensity-Matched Study (ACG 2026) - "After propensity score matching, 2,158 patients were included in each cohort. Compared with fibrates, icosapent ethyl therapy was associated with lower risk of acute pancreatitis (2.3% vs 3.8%; OR 0.59, 95% CI 0.42â0.85; P=0.004) and chronic pancreatitis (0.7% vs 1.4%; OR 0.53, 95% CI 0.29â0.98; P=0.038). Triglyceride levels were comparable between groups during follow-up (392 vs 386 mg/dL; P=0.621)."

Clinical • Real-world • Real-world evidence • Dyslipidemia • Hypertriglyceridemia • Pancreatitis • Severe Hypertriglyceridemia

Beyond Bone Health: Exploring the "Heart-Brain-Bone" Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2). (PubMed, Nutrients) - "No adequately powered randomized trial has demonstrated that the combination of long-chain omega-3, vitamin D3 and MK-7 is superior to its individual components or to placebo for any clinical endpoint. The combined regimen is therefore mechanistically rational and hypothesis-generating rather than clinically established; benefit appears most plausible in individuals with elevated risk or demonstrable nutritional insufficiency, and least in replete, low-risk populations. Findings should be interpreted within a broader healthy-aging context that includes lifestyle and psychosocial factors. Adequately powered factorial randomized controlled trials stratified by baseline Omega-3 index, 25(OH)D and vitamin K status, with prespecified mechanistic biomarkers and hard endpoints, are required."

Journal • Review • Atrial Fibrillation • Cardiovascular • Inflammation • Osteoporosis • FGF23 • MAPT • MGP

Icosapent ethyl activates GPR120 to improve post-myocardial infarction cardiac remodeling by suppressing CXCR3+ inflammatory cells. (PubMed, J Mol Cell Cardiol) - "Pharmacological inhibition of CXCR3 rescued adverse cardiac remodeling in myeloid GPR120-deficient mice, supporting a functional link between myeloid GPR120 activation and CXCR3-dependent inflammatory responses. These findings identify the myeloid GPR120-CXCL10/CXCR3 signaling axis as a critical immunomodulatory pathway by which icosapent ethyl improves post-MI cardiac remodeling, highlighting therapeutic potential of icosapent ethyl to limit inflammation-driven cardiac dysfunction after ischemic injury."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation • Myocardial Infarction • CXCL10 • CXCR3

Omega-3 Polyunsaturated Fatty Acid Formulations in Cardiovascular Prevention: Balancing Clinical Efficacy, Safety, and Environmental Sustainability. (PubMed, Nutrients) - "While traditional low-dose mixed formulations often failed to show significant benefits, high-dose purified EPA (icosapent ethyl, 4 g/day) has demonstrated a substantial reduction in residual cardiovascular risk in specific populations...Furthermore, we address the environmental burden of marine-derived oils, considering microalgae-based alternatives as sustainable solutions. Ultimately, this review advocates for a more nuanced approach that integrates clinical evidence, the potential of biomarker monitoring, and global environmental responsibility."

Biomarker • Journal • Review • Atrial Fibrillation • Cardiovascular

IPE-NaF: Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: China National Center for Cardiovascular Diseases

New P4 trial • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia

Prevalence, treatment rates and control of dyslipidemia among diabetes patients in northern Nigeria: A cross-sectional, multicenter study. (PubMed, PLoS One) - "Three-fifths of patients had dyslipidemia, but only a sixth attained the treatment target. Treatment for dyslipidemia included statins and fibrates, but not niacin, ezetimibe, bempedoic acid, icosapent ethyl, inclisiran or PCSK9 inhibitors recommended for those who failed intensive statin therapy. There is the need for better access to non-statin treatment and physician adherence to clinical practice guidelines."

Clinical • Journal • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Obesity • Renal Disease

Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year. (PubMed, Rev Cardiovasc Med) - "This review also examines the role of prolonged DAPT in selected high-risk patients (DAPT Trial, PEGASUS-Thrombolysis in Myocardial Infarction (TIMI) 54) and the paradigm of dual-pathway inhibition with low-dose rivaroxaban plus aspirin (COMPASS, VOYAGER-peripheral artery disease (PAD))...Thus, novel targets, including factor XIa inhibitors and PAR-4 antagonists, may further refine the antithrombotic approach. Overall, the optimal long-term strategy after PCI is increasingly defined not by fixed timelines but by the dynamic balance between ischemic and bleeding risk."

Journal • Review • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Hematological Disorders • Metabolic Disorders • Myocardial Infarction • Nephrology • Peripheral Arterial Disease • Renal Disease • Thrombosis • CYP2C19

Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023-2025. (PubMed, Heart Lung Circ) - "The 2023-2025 period has seen notable additions to cardiovascular pharmacotherapy in Australia, including the first cardiac myosin inhibitor, the first transthyretin stabiliser, expanded lipid lowering therapy options, and extension of SGLT2 inhibitor coverage across the heart failure ejection fraction spectrum. A pronounced access disparity persists between Australia and New Zealand."

Journal • Review • Acute Coronary Syndrome • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Dyslipidemia • Heart Failure • Hypertension • Hypertrophic Cardiomyopathy • Nephrology • Renal Disease

A Lean Metabolic Catastrophe - A Case Report on Congenital Generalized Lipodystrophy Presenting as Severe Insulin Resistance and Hypertriglyceridemia. (PubMed, Ann Afr Med) - "Congenital lipodystrophy is characterized by ectopic fat accumulation in the liver, muscles, and pancreas, with resultant severe insulin resistance and metabolic complications. Management with dual PPAR agonist therapy (saroglitazar), omega-3 fatty acids (icosapent ethyl), thiazolidinediones (pioglitazone-metformin combination), and basal insulin resulted in significant improvement in lipid and glycemic parameters on subsequent follow-ups."

Journal • Diabetes • Dyslipidemia • Hypertriglyceridemia • Lipodystrophy • Metabolic Disorders • Pain • Pancreatitis • Severe Hypertriglyceridemia

Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causality and Challenges in Therapeutic Translation. (PubMed, Curr Atheroscler Rep) - "Fibrates have produced inconsistent cardiovascular outcome results, icosapent ethyl reduces cardiovascular events but probably through mechanisms beyond triglyceride lowering alone, and potent APOC3 inhibition has failed to show short-term coronary plaque regression...TRLs are biologically and genetically linked to ASCVD, but whether lowering TRLs translates into cardiovascular risk reduction may depend on background therapy and cardiovascular risk context. Future trials must determine whether TRL-targeted therapies reduce ASCVD events beyond contemporary prevention, and in which patients this residual risk remains modifiable."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • ANGPTL3 • APOB

Drugs for hypertriglyceridemia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dyslipidemia • Hypertriglyceridemia

Aurobindo Pharma has received permission from the Food and Drug Administration for icosapent ethyl capsules, 1 gram, which are the generic of Amarin Pharmaceuticals Ireland’s Vascepa capsules (Drug Store News) - “Icosapent ethyl capsules are indicated as an adjunct to diet to reduce triglycerides levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.”

ANDA • Severe Hypertriglyceridemia